- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07728812
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy (PhenoRXPrag)
July 23, 2026 updated by: Phenomix Sciences
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy (PhenoRX Pragmatic Trial)
A pragmatic, randomized, parallel-arm, controlled study of weight loss outcomes using AOMs guided by MyPhenome test.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
424
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults - age 18 or older
- obesity (BMI ≥ 30 kg/m2) without obesity related diseases (ORDs). Or obesity (BMI ≥ 27 kg/m2) with obesity related diseases (ORDs).
- Mayo Clinic employee or dependent
- Referred to Community Internal Medicine Weight Management Program
Exclusion Criteria:
- Pregnancy or currently breast feeding.
- No contraindications to the weight loss medications: Phentermine-Topiramate Extended Release (Qsymia®); Oral naltrexone extended-release/bupropion extended-release (NBSR; Contrave®, Mysimba™); Liraglutide (Saxenda®), Semaglutide (Wegovy®), and Tirzepatide (Zepbound®).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard of Care Medication Selection
Patients randomized to this group will be prescribed the medications based on Mayo Clinic Community Internal Medicine Weight Management Program guidelines.
|
Available AOMs will be: GLP-1 Receptor Agonists (semaglutide or tirzepatide), Phentermine-Topiramate ER, and naltrexone-bupropion SR
|
|
Experimental: MyPhenome Test
Patients randomized to this group will take the MyPhenome Test.
Results will be returned and the High CTSGRS (Hungry Brain) phenotype will be assigned to Phentermine-topiramate ER, low CTSGRS (Hungry Gut) phenotype will be assigned to GLP-1 receptor agonists (semaglutide or tirzepatide) and the emotional eating phenotype will be assigned to naltrexone-bupropion SR.
|
Available AOMs will be: GLP-1 Receptor Agonists (semaglutide or tirzepatide), Phentermine-Topiramate ER, and naltrexone-bupropion SR
The MyPhenome test is a genetic and clinical assessment that classifies individuals into biologically defined obesity phenotypes to guide personalized treatment.
Using a saliva DNA sample combined with brief clinical inputs, the test predicts whether a patient has abnormalities in high CTSGRS ("Hungry Brain"), low CTSGRS ("Hungry Gut"), or hedonic eating ("Emotional Hunger").
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Body Weight Loss (TBWL) at 6 Months %
Time Frame: 6-Months
|
TWBL% at 6 months
|
6-Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TBWL% at 3 Months
Time Frame: 3-months
|
TBWL% at 3 Months
|
3-months
|
|
TBWL% at 9 Months
Time Frame: 9-Months
|
TBWL% at 9 Months
|
9-Months
|
|
TBWL% at 12 Months
Time Frame: 12-Months
|
TBWL% at 12 Months
|
12-Months
|
|
TBWL% at 18 Months
Time Frame: 18-Months
|
TBWL% at 18 Months
|
18-Months
|
|
TBWL% at 24 Months
Time Frame: 24-Months
|
TBWL% at 24 Months
|
24-Months
|
|
Degree of Treatment Response
Time Frame: 6-Months
|
6-Months: non-responsive (<3% TBWL), partial responsive (3%-15% TBWL), successful (>15%-20% TBWL) and highly successful (>20% TBWL)
|
6-Months
|
|
Cost of Treatment
Time Frame: 3, 6, 9, 12, 18, 24 Months
|
Cost of Treatment
|
3, 6, 9, 12, 18, 24 Months
|
|
Cost-Effectiveness
Time Frame: 3, 6, 9, 12, 18, 24 Months
|
Cost-Effectiveness Pharmacy resource utilization data will be collected during the study. Pharmacotherapy costs will be directly compared between control and intervention groups and compared to weight loss outcomes. |
3, 6, 9, 12, 18, 24 Months
|
|
Patient Satisfaction
Time Frame: 3, 6, 9, 12, 18, 24 Months
|
Client Satisfaction Questionnaire (CSQ-8): Given the design of the study, we will measure and evaluate patient satisfaction with a program of care rather than satisfaction with a specific medication.
The satisfaction with the program will be evaluated with the adapted Client Satisfaction Questionnaire (CSQ-8).
This is an 8-item measure that captures overall satisfaction with the care received, including perceived quality, whether care met patient needs, and willingness to recommend the program (each item score 1-4).
The items will be lightly adapted to refer to weight management care with a total score ranging from 8 to 32 .
|
3, 6, 9, 12, 18, 24 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
July 1, 2028
Study Completion (Estimated)
January 1, 2029
Study Registration Dates
First Submitted
July 10, 2026
First Submitted That Met QC Criteria
July 23, 2026
First Posted (Actual)
July 27, 2026
Study Record Updates
Last Update Posted (Actual)
July 27, 2026
Last Update Submitted That Met QC Criteria
July 23, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Overnutrition
- Body Weight
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Overweight
- Obesity
- Amino Acids, Peptides, and Proteins
- Proteins
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Health Services
- Health Care Facilities Workforce and Services
- Preventive Health Services
- Polymers
- Macromolecular Substances
- Genetic Techniques
- Genetic Services
- Diagnostic Services
- Biopolymers
- Extracellular Matrix Proteins
- Scleroproteins
- Fibrillar Collagens
- Collagen
- Therapeutics
- Genetic Testing
- Collagen Type II
Other Study ID Numbers
- PhenoRxPragmatic2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.